Bolt Biotherapeutics
BOLT
40 hedge funds and large institutions have $32.4M invested in Bolt Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 8 closing their positions.
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
21% more capital invested
Capital invested by funds: $26.8M → $32.4M (+$5.63M)
0.35% more ownership
Funds ownership: 2.73% → 3.08% (+0.35%)
9% less funds holding
Funds holding: 44 → 40 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.8M |
| 2 |
O
OrbiMed
New York
|
+$1.13M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$732K |
| 4 |
Morgan Stanley
New York
|
+$397K |
| 5 |
JP Morgan Chase
New York
|
+$248K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$364K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$164K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$52.3K |
| 4 |
NM
Newtyn Management
New York
|
-$51K |
| 5 |
EP
Eversept Partners
New York
|
-$40.5K |
BOLT Hedge Fund Activity: Q1 2023 in Review
40 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q1 2023, worth a combined $32.4M — up 21% from $26.8M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BOLT and 4 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 13 added.
The largest buyer was Tang Capital Management, adding an estimated $1.8M. The largest seller was Oasis Management Company, exiting entirely with an estimated $364K sold.
- 40 institutional investors held Bolt Biotherapeutics (BOLT) as of Q1 2023, down from 44 in Q4 2022.
- Funds reported $32.4M of Bolt Biotherapeutics stock for Q1 2023, up 21% quarter-over-quarter.
- 4 funds opened new Bolt Biotherapeutics positions in Q1 2023 and 8 closed out, a net change of -4 holders.
- The largest Bolt Biotherapeutics buyer in Q1 2023 was Tang Capital Management, an estimated $1.8M added.
- The largest Bolt Biotherapeutics seller in Q1 2023 was Oasis Management Company, an estimated $364K sold.
Based on aggregated 13F filings for Q1 2023.